This is the authors' abstract. We don't add key points for this paper.
The emergence of highly pathogenic avian influenza H5N1 viruses in Asia and their spread globally have delivered a timely reminder of the public health and clinical challenges an influenza pandemic would pose. It is remarkable how little patient-oriented clinical research has been conducted over the past 30 years on a disease that could cause such extensive loss of life. There is currently a single oral drug for the treatment of influenza (the neuraminidase inhibitor oseltamivir) and no licensed parenteral drugs, although these are being developed. A key therapeutic question recently addressed by Zheng et al.1 in an animal model is whether adjunctive interventions would improve the outcome of infection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Simmons et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: